Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Roswell Park Comprehensive Cancer Center

Sites in Buffalo, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 4:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
529
Shown on this page
12
Current sort
Recently updated
Campus scope
Roswell Park Comprehensive Cancer Center, Buffalo, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Roswell Park Comprehensive Cancer Center, Buffalo, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 457–468 of 529 matching trials with a site at Roswell Park Comprehensive Cancer Center, Buffalo, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 3 Interventional Results available

Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy

NCT04637594
Site status not listed — check the official record
View directory record Official record
Conditions
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma
Interventions
Pembrolizumab, Nivolumab, Atezolizumab, Durvalumab, Avelumab
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
377
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 260 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 26, 2026, 4:03 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

NCT02503423
Site status not listed — check the official record
View directory record Official record
Conditions
Solid Tumors, Lymphoma
Interventions
ASTX660
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
31
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 26, 2026, 4:03 AM EDT
Active, not recruiting Phase 2 Interventional

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

NCT04904588
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Lymphoma
Interventions
Busulfan, Fludarabine, Total-body irradiation, Cyclophosphamide, Melphalan, PBSC Hematopoietic Stem Cell Transplantation (HSCT), Bone Marrow Hematopoietic Stem Cell Transplantation, Post-transplant Cyclophosphamide, Mesna, Tacrolimus, Mycophenolate Mofetil, Patient-Reported Outcomes
Drug · Radiation · Procedure + 1 more
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
1 Year and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
39
States / cities
Duarte, California • San Francisco, California • Stanford, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 26, 2026, 4:03 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Implementation of Evidence-Based Strategy (PC TEACH) for the Optimization of HPV Vaccination in Rural Primary Care

NCT06256718
Site status not listed — check the official record
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
Educational Intervention
Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 26, 2026, 4:03 AM EDT
Active, not recruiting No phase listed Observational

An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study

NCT05364086
Site status not listed — check the official record
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Electronic Health Record Review, Interview, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
University of Rochester NCORP Research Base
Other
Eligibility
18 Years and older
Enrollment
2,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
259
States / cities
Jonesboro, Arkansas • Anaheim, California • Antioch, California + 203 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 26, 2026, 4:03 AM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

NCT05735184
Status at this site: Recruiting
View directory record Official record
Conditions
Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma, Nucleophosmin 1-mutated Acute Myeloid Leukemia
Interventions
Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine, Quizartinib
Drug
Lead sponsor
Kura Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
44
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 26, 2026, 4:03 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

NCT05116189
Site status not listed — check the official record
View directory record Official record
Conditions
Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms
Interventions
Pembrolizumab, Paclitaxel, Bevacizumab, Placebo for pembrolizumab, Docetaxel
Biological · Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
31
States / cities
Phoenix, Arizona • Greenbrae, California • Monterey, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 26, 2026, 4:03 AM EDT
Active, not recruiting Phase 2 Interventional

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

NCT03384914
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer Female, Breast Cancer, Male, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Residual Disease, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma
Interventions
DC1 Vaccine, WOKVAC Vaccine
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
7
States / cities
Tampa, Florida • Atlanta, Georgia • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 26, 2026, 4:03 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

NCT01349322
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer
Interventions
Standard fractionation whole breast irradiation, Hypofractionated whole breast irradiation, Concurrent boost, Sequential boost
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
2,354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
386
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 304 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 26, 2026, 4:03 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

NCT01684397
Site status not listed — check the official record
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Interventions
Bevacizumab, Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study
Biological · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
5
States / cities
Westwood, Kansas • Detroit, Michigan • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 26, 2026, 4:03 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts

NCT02933489
Site status not listed — check the official record
View directory record Official record
Conditions
Asymptomatic
Interventions
Contrast-enhanced Magnetic Resonance Imaging, Digital Tomosynthesis Mammography, Quality-of-Life Assessment, Questionnaire Administration
Diagnostic Test · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
40 Years to 75 Years · Female only
Enrollment
1,516 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
67
States / cities
Gilbert, Arizona • Pasadena, California • Denver, Colorado + 54 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 26, 2026, 4:03 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

NCT04471727
Site status not listed — check the official record
View directory record Official record
Conditions
Small-Cell Lung Cancer, Neuroendocrine Carcinoma
Interventions
Gocatamig, Atezolizumab, Ifinatamab Deruxtecan (I-DXd)
Biological
Lead sponsor
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 26, 2026, 4:03 AM EDT

About this Roswell Park Comprehensive Cancer Center institution page

What this page lists
ClinicalTrials.gov records that list Roswell Park Comprehensive Cancer Center in Buffalo, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.